Dr. Hurvitz on neoMONARCH Trial for HR+ Breast Cancer

December 9, 2016

Conference | San Antonio Breast Cancer Symposium

Sara A. Hurvitz, MD, medical oncologist, associate professor of Medicine, medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit, UCLA, discusses the findings of the neoMONARCH trial, a neoadjuvant regimen combining the CDK4/6 inhibitor abemaciclib with anastrozole, which induced a response rate of 54.7% in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

Sara A. Hurvitz, MD, medical oncologist, associate professor of Medicine, medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit, UCLA, discusses the findings of the neoMONARCH trial, a neoadjuvant regimen combining the CDK4/6 inhibitor abemaciclib with anastrozole, which induced a response rate of 54.7% in patients with hormone receptor—positive, HER2-negative early-stage breast cancer.

<<<